{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T05:20:14Z","timestamp":1770268814099,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T00:00:00Z","timestamp":1618617600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T00:00:00Z","timestamp":1618617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"DFG","award":["Digitales Operationsmikroskop\u201d INST 409\/219-1 FUGG"],"award-info":[{"award-number":["Digitales Operationsmikroskop\u201d INST 409\/219-1 FUGG"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Recurrent spontaneous epistaxis is the most common clinical manifestation and the most debilitating symptom in hereditary haemorrhagic telangiectasia (HHT) patients. To this date, there exist only a classification of HHT patients by different genetic mutations. There is no standard classification for the mucocutaneous endonasal manifestations of HHT. The aim of the present study was to document the variety of endonasal HHT lesions using digital microscopy and to propose a clinical classification.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We recorded the endonasal HHT lesions of 28 patients using a digital microscope. We reconstructed the 3D images und videos recorded by digital microscope afterwards and classified the endonasal lesions of HHT in two classes: Grade A, presence of only flat telangiectasias in the mucosa level and Grade B, (additional) presence of raised berry or wart-like telangiectasia spots. We investigated also Haemoglobin level by routine laboratory procedures, plasma VEGF level by ELISA, Severity of epistaxis by epistaxis severity score (ESS) and quality of life by a linear visual analogue scale (VAS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We found a higher quality of life and a lower severity of epistaxis in Grade A patients in comparison to Grade B patients. No difference in plasma VEGF level and in Haemoglobin between Grad A patients and Grade B patients could be detected. Plasma VEGF levels showed no gender specific differences. It could also not be correlated to the extranasal manifestation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The classification for endonasal manifestation of HHT proposed in this study indicates severity of epistaxis und quality of life. Digital microscopy with the ability of 3D reconstruction of images presents a useful tool for such classifications. The classification of endonasal HHT lesions using digital microscopy allows to evaluate the dynamic of HHT lesions in the course of time independent of examiner. This allows also to evaluate the efficacy of the different treatment modalities by dynamic of HHT lesions. Moreover digital microscopy is very beneficial in academic teaching of rare diseases.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-021-01801-9","type":"journal-article","created":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T12:02:54Z","timestamp":1618660974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Classification of endonasal HHT lesions using digital microscopy"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6198-2966","authenticated-orcid":false,"given":"F.","family":"Haubner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Schinke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bertlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. G.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Canis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Kashani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,17]]},"reference":[{"issue":"1","key":"1801_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1046\/j.1365-2796.1999.00398.x","volume":"245","author":"AD Kjeldsen","year":"1999","unstructured":"Kjeldsen AD, Vase P, Green A. Hereditary haemorrhagic telangiectasia: a population-based study of prevalence and mortality in Danish patients. J Intern Med. 1999;245(1):31\u20139.","journal-title":"J Intern Med"},{"issue":"2","key":"1801_CR2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1136\/thoraxjnl-2013-203720","volume":"69","author":"JW Donaldson","year":"2014","unstructured":"Donaldson JW, McKeever TM, Hall IP, Hubbard RB, Fogarty AW. The UK prevalence of hereditary haemorrhagic telangiectasia and its association with sex, socioeconomic status and region of residence: a population-based study. Thorax. 2014;69(2):161\u20137.","journal-title":"Thorax"},{"issue":"7","key":"1801_CR3","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1136\/jmg.2004.028712","volume":"42","author":"SG Cole","year":"2005","unstructured":"Cole SG, Begbie ME, Wallace GM, Shovlin CL. A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5. J Med Genet. 2005;42(7):577\u201382.","journal-title":"J Med Genet"},{"issue":"2","key":"1801_CR4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/ng0294-205","volume":"6","author":"CL Shovlin","year":"1994","unstructured":"Shovlin CL, Hughes JM, Tuddenham EG, Temperley I, Perembelon YF, Scott J, et al. A gene for hereditary haemorrhagic telangiectasia maps to chromosome 9q3. Nat Genet. 1994;6(2):205\u20139.","journal-title":"Nat Genet"},{"issue":"9412","key":"1801_CR5","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S0140-6736(04)15732-2","volume":"363","author":"CJ Gallione","year":"2004","unstructured":"Gallione CJ, Repetto GM, Legius E, Rustgi AK, Schelley SL, Tejpar S, et al. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet. 2004;363(9412):852\u20139.","journal-title":"Lancet"},{"issue":"4","key":"1801_CR6","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/ng1294-345","volume":"8","author":"KA McAllister","year":"1994","unstructured":"McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet. 1994;8(4):345\u201351.","journal-title":"Nat Genet"},{"issue":"5","key":"1801_CR7","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/alr.21046","volume":"2","author":"NB Sautter","year":"2012","unstructured":"Sautter NB, Smith TL. Hereditary hemorrhagic telangiectasia-related epistaxis: innovations in understanding and management. Int Forum Allergy Rhinol. 2012;2(5):422\u201331.","journal-title":"Int Forum Allergy Rhinol"},{"issue":"1","key":"1801_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13023-019-1281-4","volume":"15","author":"F Robert","year":"2020","unstructured":"Robert F, Desroches-Castan A, Bailly S, Dupuis-Girod S, Feige JJ. Future treatments for hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis. 2020;15(1):4.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1801_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000072411","volume":"110","author":"A Cirulli","year":"2003","unstructured":"Cirulli A, Liso A, D\u2019Ovidio F, Mestice A, Pasculli G, Gallitelli M, et al. Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia. Acta Haematol. 2003;110(1):29\u201332.","journal-title":"Acta Haematol"},{"issue":"4","key":"1801_CR10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1177\/1358863X18767761","volume":"23","author":"F Droege","year":"2018","unstructured":"Droege F, Thangavelu K, Stuck BA, Stang A, Lang S, Geisthoff U. Life expectancy and comorbidities in patients with hereditary hemorrhagic telangiectasia. Vasc Med. 2018;23(4):377\u201383.","journal-title":"Vasc Med"},{"key":"1801_CR11","doi-asserted-by":"publisher","unstructured":"Kennedy DW, Hwang PH, Stammberger HR, et al. Rhinology, sinonasal manifestations of systemic disease, Thieme. 2012. https:\/\/doi.org\/10.1055\/b-002-85513.","DOI":"10.1055\/b-002-85513"},{"issue":"1","key":"1801_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/194589240501900111","volume":"19","author":"BJ Folz","year":"2005","unstructured":"Folz BJ, Wollstein AC, Lippert BM, Werner JA. Morphology and distribution of nasal telangiectasia in HHT-patients with epistaxis. Am J Rhinol. 2005;19(1):65\u201370.","journal-title":"Am J Rhinol"},{"issue":"1","key":"1801_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/194589240602000116","volume":"20","author":"EJ Mahoney","year":"2006","unstructured":"Mahoney EJ, Shapshay SM. New classification of nasal vasculature patterns in hereditary hemorrhagic telangiectasia. Am J Rhinol. 2006;20(1):87\u201390.","journal-title":"Am J Rhinol"},{"issue":"5","key":"1801_CR14","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1177\/0003489419826139","volume":"128","author":"SD Kini","year":"2019","unstructured":"Kini SD, Yiu DW, Weisberg RA, Davila JF, Chelius DC. Bevacizumab as treatment for epistaxis in hereditary hemorrhagic telangiectasia: a literature review. Ann Otol Rhinol Laryngol. 2019;128(5):467\u201371.","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"6","key":"1801_CR15","first-page":"818","volume":"90","author":"H Sadick","year":"2005","unstructured":"Sadick H, Riedel F, Naim R, Goessler U, Hormann K, Hafner M, et al. Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica. 2005;90(6):818\u201328.","journal-title":"Haematologica"},{"issue":"1","key":"1801_CR16","first-page":"18","volume":"58","author":"DT Liu","year":"2020","unstructured":"Liu DT, Frohne A, Koenighofer M, Frei K, Lucas T, Riss D, et al. Plasma VEGF - a candidate biomarker for response to treatment with bevacizumab in HHT patients. Rhinology. 2020;58(1):18\u201324.","journal-title":"Rhinology"},{"issue":"1","key":"1801_CR17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P","volume":"91","author":"CL Shovlin","year":"2000","unstructured":"Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu\u2013Osler\u2013Weber syndrome). Am J Med Genet. 2000;91(1):66\u20137.","journal-title":"Am J Med Genet"},{"issue":"1","key":"1801_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1055\/s-2007-1021560","volume":"14","author":"KJ Paquet","year":"1982","unstructured":"Paquet KJ. Prophylactic endoscopic sclerosing treatment of the esophageal wall in varices\u2013a prospective controlled randomized trial. Endoscopy. 1982;14(1):4\u20135.","journal-title":"Endoscopy"},{"issue":"4","key":"1801_CR19","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/lary.20818","volume":"120","author":"JB Hoag","year":"2010","unstructured":"Hoag JB, Terry P, Mitchell S, Reh D, Merlo CA. An epistaxis severity score for hereditary hemorrhagic telangiectasia. Laryngoscope. 2010;120(4):838\u201343.","journal-title":"Laryngoscope"},{"issue":"3","key":"1801_CR20","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/lsm.23289","volume":"53","author":"M Bertlich","year":"2021","unstructured":"Bertlich M, Kashani F, Weiss BG, Wiebringhaus R, Ihler F, Freytag S, et al. Safety and efficacy of blue light laser treatment in hereditary hemorrhagic telangiectasia. Lasers Surg Med. 2021;53(3):309\u201315.","journal-title":"Lasers Surg Med."},{"issue":"3","key":"1801_CR21","first-page":"176","volume":"34","author":"T Haitjema","year":"1996","unstructured":"Haitjema T, Balder W, Disch FJ, Westermann CJ. Epistaxis in hereditary haemorrhagic telangiectasia. Rhinology. 1996;34(3):176\u20138.","journal-title":"Rhinology"},{"issue":"4","key":"1801_CR22","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1097\/00005537-200404000-00021","volume":"114","author":"JJ Jameson","year":"2004","unstructured":"Jameson JJ, Cave DR. Hormonal and antihormonal therapy for epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope. 2004;114(4):705\u20139.","journal-title":"Laryngoscope"},{"issue":"2","key":"1801_CR23","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/00000637-199508000-00017","volume":"35","author":"EE Rebeiz","year":"1995","unstructured":"Rebeiz EE, Bryan DJ, Ehrlichman RJ, Shapshay SM. Surgical management of life-threatening epistaxis in Osler\u2013Weber\u2013Rendu disease. Ann Plast Surg. 1995;35(2):208\u201313.","journal-title":"Ann Plast Surg"},{"issue":"1","key":"1801_CR24","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2500\/ajra.2009.23.3263","volume":"23","author":"F Pagella","year":"2009","unstructured":"Pagella F, Colombo A, Matti E, Giourgos G, Tinelli C, Olivieri C, et al. Correlation of severity of epistaxis with nasal telangiectasias in hereditary hemorrhagic telangiectasia (HHT) patients. Am J Rhinol Allergy. 2009;23(1):52\u20138.","journal-title":"Am J Rhinol Allergy"},{"issue":"1\u20132","key":"1801_CR25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1023\/A:1021588227705","volume":"5","author":"A Larsson","year":"2002","unstructured":"Larsson A, Sk\u00f6ldenberg E, Ericson H. Serum and plasma levels of FGF-2 and VEGF in healthy blood donors. Angiogenesis. 2002;5(1\u20132):107\u201310.","journal-title":"Angiogenesis."},{"issue":"6","key":"1801_CR26","doi-asserted-by":"publisher","first-page":"H2250","DOI":"10.1152\/ajpheart.00083.2008","volume":"295","author":"Q Hao","year":"2008","unstructured":"Hao Q, Su H, Marchuk DA, Rola R, Wang Y, Liu W, et al. Increased tissue perfusion promotes capillary dysplasia in the ALK1-deficient mouse brain following VEGF stimulation. Am J Physiol Heart Circ Physiol. 2008;295(6):H2250\u20136.","journal-title":"Am J Physiol Heart Circ Physiol."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01801-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-021-01801-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01801-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T12:05:19Z","timestamp":1618661119000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01801-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,17]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1801"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01801-9","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,17]]},"assertion":[{"value":"4 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the local ethics committee (University of Munich, Germany) under the ongoing file number 19\u2013094.The ethics committee waived the need for informed consent since the study was limited to sole data collection during regular standard practice; there were no changes in treatment caused by this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The study does not include individual person\u2019s data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"182"}}